<scp>J</scp>apan <scp>C</scp>ancer of the <scp>P</scp>rostate <scp>R</scp>isk <scp>A</scp>ssessment for combined androgen blockade including bicalutamide: Clinical application and validation

Kitagawa, Yasuhide; Hinotsu, Shiro; Shigehara, Kazuyoshi; Nakashima, Kenji; Kawaguchi, Shohei; Yaegashi, Hiroshi; Mizokami, Atsushi; Akaza, Hideyuki; Namiki, Mikio

doi:10.1111/iju.12037

Cited by 14 publications

(6 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results showed that the PFS of patients treated with CAB could be stratified by the J-CAPRA score even for a relatively short-term follow-up period, providing good external validation of the J-CAPRA scoring system ( Fig. 3) (11).…”

mentioning

confidence: 82%

Sixth Joint Meeting of J-CaP and CaPSURE--A Multinational Perspective on Prostate Cancer Management and Patient Outcomes

Akaza¹,

Hinotsu²,

Cooperberg³

et al. 2013

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

This report summarizes the presentations and discussions that took place at the Sixth Joint Meeting of J-CaP and CaPSURE held in San Francisco, USA, in August 2012. The J-CaP and CaPSURE Joint Initiative was established in 2007 with the objective of analyzing, reviewing, comparing and contrasting data for prostate cancer patients from Japan and the USA within the two important large-scale, longitudinal, observational databases-J-CaP and CaPSURE. Since this initial collaboration between teams in the USA and Japan, the initiative has now expanded to include representatives of other Asian countries, several of whom have either established or are planning their own national prostate cancer databases. Several key topics were considered at this Sixth Joint Meeting including the current status of the J-CaP and CaPSURE databases and opportunities for collaboration with the more recently developed Asian prostate cancer databases. The latest comparative data from J-CaP and CaPSURE regarding outcomes following androgen deprivation therapy and combined androgen blockade were also reviewed. The possibility of a global chemoprevention trial to investigate the influence of soy isoflavones on prostate cancer incidence was considered. In addition, the ongoing debate regarding the role of screening and the use of active surveillance as a treatment option in the USA was discussed. The collaborators agreed that sharing of data and treatment practices on a global scale would undoubtedly benefit the clinical management of prostate cancer patients worldwide.

show abstract

mentioning

confidence: 82%

Sixth Joint Meeting of J-CaP and CaPSURE--A Multinational Perspective on Prostate Cancer Management and Patient Outcomes

Akaza¹,

Hinotsu²,

Cooperberg³

et al. 2013

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…1 The validation cohort was retrospectively collected from patients treated in three institutions in Japan. A notable hallmark of the J-CAPRA score is that it is the first prediction model that is applicable to patients receiving hormonal therapy as an initial treatment for prostate cancer with or without metastases.…”

Section: Editorial Comment Editorial Comment To Japan Cancer Of the Pmentioning

confidence: 99%

“…The authors have carried out an external validation of the Japan Cancer of the Prostate Risk Assessment (J-CAPRA) score with a straight forward method in Japanese patients treated with combined androgen blockade therapy using bicalutamide as an initial treatment. 1 The validation cohort was retrospectively collected from patients treated in three institutions in Japan. A notable hallmark of the J-CAPRA score is that it is the first prediction model that is applicable to patients receiving hormonal therapy as an initial treatment for prostate cancer with or without metastases.…”

Section: Editorial Comment To Japan Cancer Of the Prostate Risk Assesmentioning

confidence: 99%

Editorial Comment to Japan Cancer of the Prostate Risk Assessment for combined androgen blockade including bicalutamide: Clinical application and validation

Yoshida

2012

Int J of Urology

View full text Add to dashboard Cite

“…9,10 To evaluate prognosis in the high number of advanced disease patients who received primary ADT, the J-CAPRA was designed. [11][12][13][14][15] We attempted to confirm the efficacy of previous risk classifications, and develop a reliable and simple model to predict oncological outcomes in patients who underwent primary ADT.…”

Section: Introductionmentioning

confidence: 99%

Simple risk assessment in prostate cancer patients treated with primary androgen deprivation therapy: The Korean Cancer Study of the Prostate risk classification

et al. 2018

View full text Add to dashboard Cite

Objectives To investigate the progression to castration‐resistant prostate cancer after primary androgen deprivation therapy, and to build a simple risk prediction model for primary androgen deprivation therapy patients based on the Japan Cancer of the Prostate Risk Assessment criteria. Methods A total of 602 patients who received primary androgen deprivation therapy were entered into the Korean Cancer Study of the Prostate database. The effect of prognostic factors was determined by multivariate analysis. For each patient, the weight of all factors was totaled to give Korean Cancer Study‐prostate scores; patients were divided into three risk groups according to their score. The probability of castration‐resistant prostate cancer, cancer‐specific survival and overall survival was estimated by Kaplan–Meier analysis. Results On multivariate analysis for castration‐resistant prostate cancer, the significant variables were initial prostate‐specific antigen (>40 ng/mL; 1 point), biopsy Gleason score (≥9; 1 point), clinical N1 (1 point), and non‐regional lymph node (1 point), bone (1 point) and visceral (1 point) metastasis. The Korean Cancer Study‐prostate scoring model was calculated on a scale of 0–6 (0: low, 1–2: intermediate, ≥3: high risk). The risk groups stratified castration‐resistant prostate cancer (P < 0.0001), cancer‐specific survival (P < 0.0001) and overall survival (P < 0.0001) by Kaplan–Meier curve. The Korean Cancer Study‐prostate model predicted castration‐resistant prostate cancer with a c‐index of 0.7242, cancer‐specific survival with a c‐index of 0.7036 and overall survival with a c‐index of 0.5890. The 5‐year estimated castration‐resistant prostate cancer/cancer‐specific death rates were 10.3%/6.3% in the low‐risk group, 48.4%/22.2% in the intermediate‐risk group and 81.7%/53.1% in the high‐risk group. Conclusions The Korean Cancer Study‐prostate risk classification, a modified Japan Cancer of the Prostate Risk Assessment model, is a simple scoring model for predicting oncological outcomes after primary androgen deprivation therapy.

show abstract

Japan Cancer of the Prostate Risk Assessment for combined androgen blockade including bicalutamide: Clinical application and validation

Cited by 14 publications

References 23 publications

Sixth Joint Meeting of J-CaP and CaPSURE--A Multinational Perspective on Prostate Cancer Management and Patient Outcomes

Sixth Joint Meeting of J-CaP and CaPSURE--A Multinational Perspective on Prostate Cancer Management and Patient Outcomes

Editorial Comment to Japan Cancer of the Prostate Risk Assessment for combined androgen blockade including bicalutamide: Clinical application and validation

Simple risk assessment in prostate cancer patients treated with primary androgen deprivation therapy: The Korean Cancer Study of the Prostate risk classification

Contact Info

Product

Resources

About